Deutsche Märkte geschlossen

Biogen Inc. (BIIB)

NasdaqGS - NasdaqGS Echtzeitpreis. Währung in USD
Zur Watchlist hinzufügen
224,00-1,58 (-0,70%)
Börsenschluss: 04:00PM EDT
222,00 -2,00 (-0,89%)
Nachbörse: 05:46PM EDT

Biogen Inc.

225 Binney Street
Cambridge, MA 02142
United States
617 679 2000
https://www.biogen.com

Sektor(en)Healthcare
BrancheDrug Manufacturers—General
Vollzeitmitarbeiter7.570

Leitende Angestellte

NameTitelZahlenAusgeübtGeburtsjahr
Mr. Christopher A. ViehbacherPresident, CEO & Director4,07MN/A1961
Mr. Michael R. McDonnell CPAExecutive VP & CFO2,21MN/A1964
Ms. Nicole MurphyHead of Pharmaceutical Operations & Technology1,45MN/A1973
Ms. Susan H. Alexander Esq.Executive VP & Chief Legal Officer1,95MN/A1957
Mr. Rachid IzzarHead of Global Product Strategy & Commercialization1,27MN/A1975
Ms. Robin C. KramerSenior VP & Chief Accounting OfficerN/AN/A1966
Mr. Charles E. TrianoSenior VP & Head of Investor RelationsN/AN/AN/A
Ms. Natacha GassenbachChief Communication Officer & Head of Corporate AffairsN/AN/AN/A
Mr. Adam Keeney Ph.D.Executive VP & Head of Corporate DevelopmentN/AN/A1977
Dr. Ginger Gregory Ph.D.Executive VP & Chief Human Resources Officer1,59MN/A1968
Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Biogen Inc.s ISS Governance QualityScore, Stand 1. Juni 2024, lautet 2. Die grundlegenden Scores sind Audit: 8, Vorstand: 1, Shareholderrechte: 2, Kompensation: 6.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.